Health Affairs, 28, no. 4 (2009): 1199-1209 doi: 10.1377/hlthaff.28.4.1199 © 2009 by Project HOPE	New Online   Senate Health Reform Bill   Rewarding Providers   Public Option Policy Brief   Health Reform & Abortion   Delivery System Reform

This Article Figures Only Full Text (HTML) Reprint (PDF) Technical Supplement Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Google Scholar Articles by Brooke, B. S. Articles by Pronovost, P. J. PubMed PubMed Citation Articles by Brooke, B. S. Articles by Pronovost, P. J. Related Collections Hospitals Physicians Quality Of Care Evidence-Based Medicine

DataWatch

Use Of Beta-Blockers During Aortic Aneurysm Repair: Bridging The Gap Between Evidence And Effective Practice

The Leapfrog Group aims to improve patient safety and outcomes in hospitals through promoting the routine use of evidence-based medicine (EBM) practices such as the perioperative use of beta-blocker medications during elective abdominal aortic aneurysm (AAA) repair. The emergence of recent evidence, however, has sparked debate about the benefits of this practice. We found that implementation of the Leapfrog Group’s beta-blocker standard in California hospitals has led to an estimated 50 percent decrease in mortality following open AAA repair over time. The efficacy and effectiveness of specific EBM practices must be continually reexamined, to ensure that objectives are being met.

                      What's this?